{"id":6948,"date":"2025-05-15T15:48:58","date_gmt":"2025-05-15T13:48:58","guid":{"rendered":"https:\/\/value-dossier.com\/homepage\/"},"modified":"2026-04-14T11:29:35","modified_gmt":"2026-04-14T09:29:35","slug":"homepage","status":"publish","type":"page","link":"https:\/\/value-dossier.com\/en\/","title":{"rendered":"Homepage"},"content":{"rendered":"\n<section class=\"wrap_outer intro no-spacing\">\n    <div class=\"wrap_inner\">\n\n        <div class=\"intro__text\">\n            <div class=\"okd-text\">\n                <h1>Your <strong>Specialists<\/strong> for Market Access and Reimbursement<\/h1>\n<p>Value &amp; Dossier advises Pharmaceutical and Biotechnology Companies in the AMNOG Process and in all matters of Market Access and Reimbursement.<\/p>\n            <\/div>\n            <div class=\"intro__contact\">\n                                    <a class=\"button\" href=\"https:\/\/value-dossier.com\/en\/services\/\" target=\"_self\">Our services<\/a>\n                                                    <a href=\"tel:+49 6173 \/ 39 41 0 16\" class=\"button button-ghost button-phone\">+49 6173 \/ 39 41 0 16<\/a>\n                            <\/div>\n        <\/div>\n\n    <\/div>\n\n    <img loading=\"lazy\" decoding=\"async\" width=\"2560\" height=\"1440\" src=\"https:\/\/value-dossier.com\/wp-content\/uploads\/2026\/03\/team-kv-2.jpg\" class=\"attachment-full size-full\" alt=\"\" srcset=\"https:\/\/value-dossier.com\/wp-content\/uploads\/2026\/03\/team-kv-2.jpg 2560w, https:\/\/value-dossier.com\/wp-content\/uploads\/2026\/03\/team-kv-2-300x169.jpg 300w, https:\/\/value-dossier.com\/wp-content\/uploads\/2026\/03\/team-kv-2-1024x576.jpg 1024w, https:\/\/value-dossier.com\/wp-content\/uploads\/2026\/03\/team-kv-2-768x432.jpg 768w, https:\/\/value-dossier.com\/wp-content\/uploads\/2026\/03\/team-kv-2-1536x864.jpg 1536w, https:\/\/value-dossier.com\/wp-content\/uploads\/2026\/03\/team-kv-2-2048x1152.jpg 2048w\" sizes=\"auto, (max-width: 2560px) 100vw, 2560px\" \/>\n<\/section>\n\n\n<section class=\"wrap_outer tiles background-shift\">\n    <div class=\"wrap_inner\">\n\n        \n            <div class=\"tiles__single background-map__de\">\n                                    <div class=\"badge\">AMNOG<\/div>\n                                <h2>Health Technology Assessment in Germany at a Glance<\/h2>\n                                <div class=\"tiles__single-links\">\n                                            <a class=\"button button-secondary\" href=\"https:\/\/value-dossier.com\/en\/german-benefit-assessment-amnog\/\" target=\"_self\">Learn more<\/a>\n                                            <a class=\"button button-ghost button-watch-white\" href=\"https:\/\/value-dossier.com\/en\/german-benefit-assessment-amnog\/\" target=\"_self\">Watch video<\/a>\n                                    <\/div>\n                            <\/div>\n\n        \n            <div class=\"tiles__single background-map__eu\">\n                                    <div class=\"badge\">JCA<\/div>\n                                <h2>Navigating Every Phase of the New EU-HTA Process<\/h2>\n                                <div class=\"tiles__single-links\">\n                                            <a class=\"button button-secondary\" href=\"https:\/\/value-dossier.com\/en\/european-health-technology-assessment-eu-hta\/\" target=\"_self\">Learn more<\/a>\n                                            <a class=\"button button-ghost button-watch-white\" href=\"https:\/\/value-dossier.com\/en\/european-health-technology-assessment-eu-hta\/\" target=\"_self\">Watch video<\/a>\n                                    <\/div>\n                            <\/div>\n\n        \n    <\/div>\n<\/section>\n\n\n<section class=\"wrap_outer linked-images\" id=\"okd-block-3\">\n    <div class=\"wrap_inner\">\n\n                    <div class=\"okd-text\">\n                <h2>Our services<\/h2>\n            <\/div>\n        \n        <div class=\"linked-images__wrapper\">\n\n            <div class=\"links\">\n\n                                    <div class=\"link\" data-image=\"1\">\n                                                    <a href=\"https:\/\/value-dossier.com\/en\/dossiers-and-medical-writing\/\" target=\"_self\"><\/a>\n                                                <div class=\"okd-text\">\n                            <h3>Medical Writing and Statistical Services for Dossiers<\/h3>\n                            <p>Strategic dossier development with medical writing and statistical expertise for AMNOG and EU HTA<\/p>\n                        <\/div>\n                    <\/div>\n                                        <div class=\"link\" data-image=\"2\">\n                                                    <a href=\"https:\/\/value-dossier.com\/en\/strategic-market-access-consulting\/\" target=\"_self\"><\/a>\n                                                <div class=\"okd-text\">\n                            <h3>Strategic Market Access Consulting<\/h3>\n                            <p>Tailored strategies for your product with our HTA expertise, gap and market analyses, our reference price calculator and more<\/p>\n                        <\/div>\n                    <\/div>\n                                        <div class=\"link\" data-image=\"3\">\n                                                    <a href=\"https:\/\/value-dossier.com\/en\/hearing-and-negotiation-training\/\" target=\"_self\"><\/a>\n                                                <div class=\"okd-text\">\n                            <h3>Trainings for Hearings and Negotiations<\/h3>\n                            <p>Confidently through every step of the process: preparation, strategy, and training for successful reimbursement negotiations.<\/p>\n                        <\/div>\n                    <\/div>\n                                        <div class=\"link\" data-image=\"4\">\n                                                    <a href=\"https:\/\/value-dossier.com\/en\/fixed-price-analyses\/\" target=\"_self\"><\/a>\n                                                <div class=\"okd-text\">\n                            <h3>Reference Price Analyses<\/h3>\n                            <p>Reference price simulations for better pricing decisions.<\/p>\n                        <\/div>\n                    <\/div>\n                    \n            <\/div>\n\n            <div class=\"images\">\n\n                                    <div class=\"image\" data-link=\"1\">\n                        <img loading=\"lazy\" decoding=\"async\" width=\"1920\" height=\"1280\" src=\"https:\/\/value-dossier.com\/wp-content\/uploads\/2026\/01\/vd-praesentation-04.jpg\" class=\"attachment-full size-full\" alt=\"\" srcset=\"https:\/\/value-dossier.com\/wp-content\/uploads\/2026\/01\/vd-praesentation-04.jpg 1920w, https:\/\/value-dossier.com\/wp-content\/uploads\/2026\/01\/vd-praesentation-04-300x200.jpg 300w, https:\/\/value-dossier.com\/wp-content\/uploads\/2026\/01\/vd-praesentation-04-1024x683.jpg 1024w, https:\/\/value-dossier.com\/wp-content\/uploads\/2026\/01\/vd-praesentation-04-768x512.jpg 768w, https:\/\/value-dossier.com\/wp-content\/uploads\/2026\/01\/vd-praesentation-04-1536x1024.jpg 1536w\" sizes=\"auto, (max-width: 1920px) 100vw, 1920px\" \/>                    <\/div>\n                                        <div class=\"image\" data-link=\"2\">\n                        <img loading=\"lazy\" decoding=\"async\" width=\"1920\" height=\"1280\" src=\"https:\/\/value-dossier.com\/wp-content\/uploads\/2026\/01\/vd-praesentation-09.jpg\" class=\"attachment-full size-full\" alt=\"\" srcset=\"https:\/\/value-dossier.com\/wp-content\/uploads\/2026\/01\/vd-praesentation-09.jpg 1920w, https:\/\/value-dossier.com\/wp-content\/uploads\/2026\/01\/vd-praesentation-09-300x200.jpg 300w, https:\/\/value-dossier.com\/wp-content\/uploads\/2026\/01\/vd-praesentation-09-1024x683.jpg 1024w, https:\/\/value-dossier.com\/wp-content\/uploads\/2026\/01\/vd-praesentation-09-768x512.jpg 768w, https:\/\/value-dossier.com\/wp-content\/uploads\/2026\/01\/vd-praesentation-09-1536x1024.jpg 1536w\" sizes=\"auto, (max-width: 1920px) 100vw, 1920px\" \/>                    <\/div>\n                                        <div class=\"image\" data-link=\"3\">\n                        <img loading=\"lazy\" decoding=\"async\" width=\"1920\" height=\"1280\" src=\"https:\/\/value-dossier.com\/wp-content\/uploads\/2026\/01\/vd-praesentation-20.jpg\" class=\"attachment-full size-full\" alt=\"\" srcset=\"https:\/\/value-dossier.com\/wp-content\/uploads\/2026\/01\/vd-praesentation-20.jpg 1920w, https:\/\/value-dossier.com\/wp-content\/uploads\/2026\/01\/vd-praesentation-20-300x200.jpg 300w, https:\/\/value-dossier.com\/wp-content\/uploads\/2026\/01\/vd-praesentation-20-1024x683.jpg 1024w, https:\/\/value-dossier.com\/wp-content\/uploads\/2026\/01\/vd-praesentation-20-768x512.jpg 768w, https:\/\/value-dossier.com\/wp-content\/uploads\/2026\/01\/vd-praesentation-20-1536x1024.jpg 1536w\" sizes=\"auto, (max-width: 1920px) 100vw, 1920px\" \/>                    <\/div>\n                                        <div class=\"image\" data-link=\"4\">\n                        <img loading=\"lazy\" decoding=\"async\" width=\"1920\" height=\"1280\" src=\"https:\/\/value-dossier.com\/wp-content\/uploads\/2026\/01\/vd-praesentation-06.jpg\" class=\"attachment-full size-full\" alt=\"\" srcset=\"https:\/\/value-dossier.com\/wp-content\/uploads\/2026\/01\/vd-praesentation-06.jpg 1920w, https:\/\/value-dossier.com\/wp-content\/uploads\/2026\/01\/vd-praesentation-06-300x200.jpg 300w, https:\/\/value-dossier.com\/wp-content\/uploads\/2026\/01\/vd-praesentation-06-1024x683.jpg 1024w, https:\/\/value-dossier.com\/wp-content\/uploads\/2026\/01\/vd-praesentation-06-768x512.jpg 768w, https:\/\/value-dossier.com\/wp-content\/uploads\/2026\/01\/vd-praesentation-06-1536x1024.jpg 1536w\" sizes=\"auto, (max-width: 1920px) 100vw, 1920px\" \/>                    <\/div>\n                    \n            <\/div>\n\n        <\/div>\n\n        <script>\n            jQuery(function($) {\n\n                const section = $('#okd-block-3'),\n                    links = section.find('.links'),\n                    images = section.find('.images');\n\n                links.find('.link').on('mouseover', function() {\n\n                    let imageId = $(this).attr('data-image');\n                    images.find('.image').css('opacity', '0');\n                    images.find(`.image[data-link=\"${imageId}\"]`).css('opacity', '1');\n\n                });\n\n            });\n        <\/script>\n\n    <\/div>\n<\/section>\n\n\n<section class=\"wrap_outer cta-break\">\n    <div class=\"wrap_inner\">\n\n        <div class=\"cta-break__wrapper\">\n\n                            <div class=\"badge\">AMNOG<\/div>\n            \n            <div class=\"okd-text\">\n                <h2>AMNOG Negotiation Guide<\/h2>\n                                    <p>Our AMNOG tool gives you a compact overview of the possible price range for your product.<\/p>\n                                                    <p>\n                        <a href=\"https:\/\/value-dossier.com\/en\/amnog-negotiation-guide\/\" target=\"_self\" class=\"button button-secondary button-calc\">Calculate<\/a>\n                    <\/p>\n                            <\/div>\n\n        <\/div>\n\n    <\/div>\n<\/section>\n\n\n<section class=\"wrap_outer text-image\">\n    <div class=\"wrap_inner\">\n\n        <div class=\"text\">\n            <div class=\"okd-text\">\n                <h2>Your partner for <strong>successful<\/strong> market access and reimbursement of pharmaceuticals and medical devices<\/h2>\n<p>Our experienced team supports pharmaceutical companies in bringing new products to market \u2013 whether through the German or the European procedure. From strategic planning and dossier preparation to successful price negotiations, we guide you safely through the entire health technology assessment process. We offer customized, business-specific solutions that highlight the value of your product and translate it effectively into benefit dossiers. Our expertise covers all aspects of the market access process, including reimbursement support and topics such as reference pricing, rebate contracts, and market analyses.   <\/p>\n            <\/div>\n        <\/div>\n\n        <div class=\"image\">\n            <img loading=\"lazy\" decoding=\"async\" width=\"1920\" height=\"1280\" src=\"https:\/\/value-dossier.com\/wp-content\/uploads\/2026\/01\/vd-praesentation-02.jpg\" class=\"attachment-full size-full\" alt=\"\" srcset=\"https:\/\/value-dossier.com\/wp-content\/uploads\/2026\/01\/vd-praesentation-02.jpg 1920w, https:\/\/value-dossier.com\/wp-content\/uploads\/2026\/01\/vd-praesentation-02-300x200.jpg 300w, https:\/\/value-dossier.com\/wp-content\/uploads\/2026\/01\/vd-praesentation-02-1024x683.jpg 1024w, https:\/\/value-dossier.com\/wp-content\/uploads\/2026\/01\/vd-praesentation-02-768x512.jpg 768w, https:\/\/value-dossier.com\/wp-content\/uploads\/2026\/01\/vd-praesentation-02-1536x1024.jpg 1536w\" sizes=\"auto, (max-width: 1920px) 100vw, 1920px\" \/>            <div class=\"trust-kpi\">\n                <div class=\"icon\">\n                    <svg width=\"48\" height=\"48\" viewBox=\"0 0 48 48\" fill=\"none\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\">\n                        <path d=\"M20 6H8C6.89543 6 6 6.89543 6 8V40C6 41.1046 6.89543 42 8 42H20C21.1046 42 22 41.1046 22 40V8C22 6.89543 21.1046 6 20 6Z\" stroke=\"#0F466B\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\"\/>\n                        <path d=\"M14 6V42\" stroke=\"#0F466B\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\"\/>\n                        <path d=\"M40.8 37.8C41.2 38.8 40.6 40 39.6 40.4L35.8 41.8C34.8 42.2 33.6 41.6 33.2 40.6L22.2 10.2C21.8 9.2 22.4 8 23.4 7.6L27.2 6.2C28.2 5.8 29.4 6.4 29.8 7.4L40.8 37.8Z\" stroke=\"#0F466B\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\"\/>\n                    <\/svg>\n                <\/div>\n                <div class=\"label\">\n                    <div><strong class=\"h2\">150+<\/strong> written dossiers<\/div>\n                <\/div>\n            <\/div>\n                    <\/div>\n\n    <\/div>\n<\/section>\n\n\n<section class=\"wrap_outer trust background-shift\">\n    <div class=\"wrap_inner\">\n\n                    <div class=\"tile tile-image\">\n                <img loading=\"lazy\" decoding=\"async\" width=\"1562\" height=\"838\" src=\"https:\/\/value-dossier.com\/wp-content\/uploads\/2026\/02\/frankfurt-am-main-e1770117690773.jpg\" class=\"attachment-full size-full\" alt=\"\" srcset=\"https:\/\/value-dossier.com\/wp-content\/uploads\/2026\/02\/frankfurt-am-main-e1770117690773.jpg 1562w, https:\/\/value-dossier.com\/wp-content\/uploads\/2026\/02\/frankfurt-am-main-e1770117690773-300x161.jpg 300w, https:\/\/value-dossier.com\/wp-content\/uploads\/2026\/02\/frankfurt-am-main-e1770117690773-1024x549.jpg 1024w, https:\/\/value-dossier.com\/wp-content\/uploads\/2026\/02\/frankfurt-am-main-e1770117690773-768x412.jpg 768w, https:\/\/value-dossier.com\/wp-content\/uploads\/2026\/02\/frankfurt-am-main-e1770117690773-1536x824.jpg 1536w\" sizes=\"auto, (max-width: 1562px) 100vw, 1562px\" \/>            <\/div>\n        \n        \n                <div class=\"tile tile-linkedin\">\n            <span><\/span>\n            <div class=\"h3\">WS Value &#038; Dossier GmbH<\/div>\n            <a href=\"https:\/\/de.linkedin.com\/company\/value-dossier\" target=\"_blank\" rel=\"noopener nofollow\" class=\"read-more\">Follow us on LinkedIn<\/a>\n        <\/div>\n        \n                    <div class=\"tile tile-image\">\n                <img loading=\"lazy\" decoding=\"async\" width=\"1536\" height=\"1024\" src=\"https:\/\/value-dossier.com\/wp-content\/uploads\/2026\/02\/team-tile-e1776148646911.jpg\" class=\"attachment-full size-full\" alt=\"\" \/>            <\/div>\n        \n                    <div class=\"tile tile-quote\">\n                <p>After more than 25 years of experience in market access, we are still fascinated by the unique strategic and substantive challenges that each individual project brings. Our clients\u2019 success is what drives us and fuels our ambition. We approach every project with passion and provide high-quality analyses and customized solutions that best serve our clients\u2019 interests.<\/p>\n                <div class=\"quote-author\">\n                    <p>\n                        <strong>Dr. Willi Schnorpfeil<\/strong><br>\n                        Managing Director                    <\/p>\n                <\/div>\n            <\/div>\n        \n                    <div class=\"tile tile-claim\">\n                                    <div class=\"h2\">tailored<\/div>\n                                    <div class=\"h2\">flexible<\/div>\n                                    <div class=\"h2\">high-quality<\/div>\n                            <\/div>\n        \n    <\/div>\n<\/section>\n\n\n<section class=\"wrap_outer latest-posts\">\n    <div class=\"wrap_inner\">\n\n                    <div class=\"okd-text\">\n                <h2>Latest posts<\/h2>\n            <\/div>\n        \n                    <div class=\"posts\">\n\n                \n                    <article>\n                        <div class=\"post-image\">\n                            <img loading=\"lazy\" decoding=\"async\" width=\"963\" height=\"402\" src=\"https:\/\/value-dossier.com\/wp-content\/uploads\/2024\/04\/Value-Dossier-Reference-pricing-for-pharmaceuticals_en__s-1.jpg\" class=\"attachment-full size-full wp-post-image\" alt=\"\" srcset=\"https:\/\/value-dossier.com\/wp-content\/uploads\/2024\/04\/Value-Dossier-Reference-pricing-for-pharmaceuticals_en__s-1.jpg 963w, https:\/\/value-dossier.com\/wp-content\/uploads\/2024\/04\/Value-Dossier-Reference-pricing-for-pharmaceuticals_en__s-1-300x125.jpg 300w, https:\/\/value-dossier.com\/wp-content\/uploads\/2024\/04\/Value-Dossier-Reference-pricing-for-pharmaceuticals_en__s-1-768x321.jpg 768w\" sizes=\"auto, (max-width: 963px) 100vw, 963px\" \/>                            <a href=\"https:\/\/value-dossier.com\/en\/pediatric-drug-shortages\/\"><\/a>\n                        <\/div>\n                        <div class=\"okd-text\">\n                            <h3><a href=\"https:\/\/value-dossier.com\/en\/pediatric-drug-shortages\/\">Pediatric drug shortages<\/a><\/h3>\n                            <p>Pediatric drug shortages: has the situation really improved? In recent years, Germany has faced shortages of essential medicines for children, including antipyretics and antibiotics. To encourage manufacturers to increase production and supply, the GKV-SV (GKV-Spitzenverband, German SHI association)\u2026<\/p>\n                        <\/div>\n                        <a href=\"https:\/\/value-dossier.com\/en\/pediatric-drug-shortages\/\" class=\"read-more\">Read post<\/a>\n                    <\/article>\n\n                \n                    <article>\n                        <div class=\"post-image\">\n                            <img loading=\"lazy\" decoding=\"async\" width=\"2560\" height=\"2144\" src=\"https:\/\/value-dossier.com\/wp-content\/uploads\/2025\/11\/EU_HTA_Mitgliedsstaaten-scaled-e1772088892750.png\" class=\"attachment-full size-full wp-post-image\" alt=\"\" \/>                            <a href=\"https:\/\/value-dossier.com\/en\/start-of-eu-hta-first-joint-assessments-with-iqwig-involvement\/\"><\/a>\n                        <\/div>\n                        <div class=\"okd-text\">\n                            <h3><a href=\"https:\/\/value-dossier.com\/en\/start-of-eu-hta-first-joint-assessments-with-iqwig-involvement\/\">Start of EU-HTA: First Joint Assessments with IQWiG Involvement<\/a><\/h3>\n                            <p>Since the beginning of 2025, member states of the European Economic Area (EEA) have been working together on joint clinical assessments (JCA) of new medicines. Recently, the first 9 JCAs were announced, assessing 2 ATMPs with Orphan drug status and 7 oncologics. Germany, France, and Ireland are curr\u2026<\/p>\n                        <\/div>\n                        <a href=\"https:\/\/value-dossier.com\/en\/start-of-eu-hta-first-joint-assessments-with-iqwig-involvement\/\" class=\"read-more\">Read post<\/a>\n                    <\/article>\n\n                \n                    <article>\n                        <div class=\"post-image\">\n                            <img decoding=\"async\" src=\"https:\/\/value-dossier.com\/wp-content\/uploads\/2025\/02\/AMNOG-Leitplanken-scaled-1.jpg\" alt=\"\">                            <a href=\"https:\/\/value-dossier.com\/en\/pharmaceutical-companies-with-rd-in-germany-benefit-for-price-negotiations\/\"><\/a>\n                        <\/div>\n                        <div class=\"okd-text\">\n                            <h3><a href=\"https:\/\/value-dossier.com\/en\/pharmaceutical-companies-with-rd-in-germany-benefit-for-price-negotiations\/\">Pharmaceutical companies with R&amp;D in Germany \u2013 Benefit for price negotiations<\/a><\/h3>\n                            <p>Products with initial market entry after January 1st, 2025 are now benefiting from less strict pricing guidelines if the studies used for AMNOG benefit assessment included \u2265 5 % German patients. The benefit will last for 3 years and can be maintained even afterwards for companies with active R&amp;D\u2026<\/p>\n                        <\/div>\n                        <a href=\"https:\/\/value-dossier.com\/en\/pharmaceutical-companies-with-rd-in-germany-benefit-for-price-negotiations\/\" class=\"read-more\">Read post<\/a>\n                    <\/article>\n\n                \n                    <article>\n                        <div class=\"post-image\">\n                            <img decoding=\"async\" src=\"https:\/\/value-dossier.com\/wp-content\/uploads\/2025\/01\/Referenzpreise.jpg\" alt=\"\">                            <a href=\"https:\/\/value-dossier.com\/en\/european-reference-pricing-is-discontinued-in-germany\/\"><\/a>\n                        <\/div>\n                        <div class=\"okd-text\">\n                            <h3><a href=\"https:\/\/value-dossier.com\/en\/european-reference-pricing-is-discontinued-in-germany\/\">European Reference Pricing is discontinued in Germany<\/a><\/h3>\n                            <p>Changes to the German pricing system for innovative drugs are now in effect due to the Medical Research Act (Medizinforschungsgesetz, MFG). As of January 1st, 2025, European reference prices will no longer be included in the price negotiations according to \u00a7 130b SGB V following AMNOG benefit assess\u2026<\/p>\n                        <\/div>\n                        <a href=\"https:\/\/value-dossier.com\/en\/european-reference-pricing-is-discontinued-in-germany\/\" class=\"read-more\">Read post<\/a>\n                    <\/article>\n\n                \n            <\/div>\n            \n        \n    <\/div>\n<\/section>","protected":false},"excerpt":{"rendered":"","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_acf_changed":false,"footnotes":""},"class_list":["post-6948","page","type-page","status-publish","hentry"],"acf":[],"_links":{"self":[{"href":"https:\/\/value-dossier.com\/en\/wp-json\/wp\/v2\/pages\/6948","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/value-dossier.com\/en\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/value-dossier.com\/en\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/value-dossier.com\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/value-dossier.com\/en\/wp-json\/wp\/v2\/comments?post=6948"}],"version-history":[{"count":29,"href":"https:\/\/value-dossier.com\/en\/wp-json\/wp\/v2\/pages\/6948\/revisions"}],"predecessor-version":[{"id":7915,"href":"https:\/\/value-dossier.com\/en\/wp-json\/wp\/v2\/pages\/6948\/revisions\/7915"}],"wp:attachment":[{"href":"https:\/\/value-dossier.com\/en\/wp-json\/wp\/v2\/media?parent=6948"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}